Global Cancer Companion Diagnostic Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Cancer Companion Diagnostic Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Companion diagnostic (CD) is an in vitro diagnostic technology that can provide information about a patient's therapeutic response to a specific therapeutic drug, helping to identify patient groups who can benefit from a certain therapeutic product, thereby improving treatment prognosis. and reduce health care costs. Additionally, companion diagnostics can help identify patient populations most likely to respond to therapeutic agents. The companion diagnostics market is still in its early stages.
Global Cancer Companion Diagnostic market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Demand from Lung Cancer and Colorectal Cancer are the major drivers for the industry."&
The number of cancer patients is gradually increasing, drug accessibility is improving, and the research and development of targeted drugs and immunotherapy continue to increase. This is the main trend of drug development in the next ten years.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Cancer Companion Diagnostic market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
AmoyDx
Novogene
Illumina
Roche
Agilent
Abbott
Thermo Fisher
Qiagen
Guardant Health
Segment by Type
Polymerase Chain Reaction (PCR)
“Next Generation” Sequencing (NGS)
Fluorescence In Situ Hybridization (FISH)
Immunohistochemistry (IHC)
Lung Cancer
Colorectal Cancer
Breast Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Cancer Companion Diagnostic market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Cancer Companion Diagnostic introduction, etc. Cancer Companion Diagnostic Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of Cancer Companion Diagnostic market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.
Global Cancer Companion Diagnostic market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Demand from Lung Cancer and Colorectal Cancer are the major drivers for the industry."&
The number of cancer patients is gradually increasing, drug accessibility is improving, and the research and development of targeted drugs and immunotherapy continue to increase. This is the main trend of drug development in the next ten years.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Cancer Companion Diagnostic market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
AmoyDx
Novogene
Illumina
Roche
Agilent
Abbott
Thermo Fisher
Qiagen
Guardant Health
Segment by Type
Polymerase Chain Reaction (PCR)
“Next Generation” Sequencing (NGS)
Fluorescence In Situ Hybridization (FISH)
Immunohistochemistry (IHC)
Segment by Application
Lung Cancer
Colorectal Cancer
Breast Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Cancer Companion Diagnostic market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Cancer Companion Diagnostic introduction, etc. Cancer Companion Diagnostic Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of Cancer Companion Diagnostic market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices